Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BAY 1128688 dose-response study in women with symptomatic endometriosis
2017-000244-18Phase 2Terminated
- Sponsor
- Bayer
- Start
- Jul 2017
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of BAY1128688 in endometriosis (5 arms), sponsored by Bayer. Primary endpoint: Change in mean pain of the 7 days with worst endometriosis-associated pelvic pain. Started Jul 2017; status: terminated.
02
Drugs
BAY1128688
03
Conditions
endometriosis
Beyond the preview
Go deeper on 2017-000244-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-000244-18.